$135.99
-1.77[-1.28%]
At close: Apr 26
$135.99
0[0.00%]
After Hours: 4:00PM EDT
Neurocrine Biosciences
(NASDAQ:NBIX)Latest News for Neurocrine Biosciences Stock (NASDAQ:NBIX)
Neurocrine Biosciences Stock (NASDAQ: NBIX)
Categories: All
Wednesday, April 24, 2024
- Wells Fargo Upgrades Neurocrine Biosciences to Overweight, Raises Price Target to $170Benzinga Newsdesk - 4 days ago
- Oppenheimer Maintains Outperform on Neurocrine Biosciences, Maintains $200 Price TargetBenzinga Newsdesk - 4 days ago
- HC Wainwright & Co. Reiterates Buy on Neurocrine Biosciences, Maintains $150 Price TargetBenzinga Newsdesk - 4 days ago
Tuesday, April 23, 2024
- Neurocrine Biosciences Says Treatment Can Alleviate Several Symptoms Associated With Depressive DisorderVandana Singh - 5 days ago
- Needham Reiterates Hold on Neurocrine BiosciencesBenzinga Newsdesk - 5 days ago
- Neurocrine Biosciences shares are trading higher after the company's Phase 2 SAVITRI study met its primary endpoint in major depressive disorder.Benzinga Newsdesk - 5 days ago
- Neurocrine Biosciences Says Phase 2 SAVITRI Study Met Primary Endpoint For Adults With Major Depressive DisorderBenzinga Newsdesk - 5 days ago
Wednesday, April 17, 2024
Tuesday, April 16, 2024
- Sentia Medical Sciences Further Extends Research Collaboration With Neurocrine Biosciences To Discover Novel CRF PeptidesBenzinga Newsdesk - Apr 16, 2024, 4:02PM
- Selection Of The Development Candidate Triggered A $3M Milestone Payment To Voyager, Which The Company Expects To Receive In Q2 Of 2024Benzinga Newsdesk - Apr 16, 2024, 7:12AM
- Voyager Therapeutics And Neurocrine Biosciences Expect To File An FDA Investigational New Drug Application For GBA1 Program Candidate In 2025Benzinga Newsdesk - Apr 16, 2024, 7:07AM
- Voyager Therapeutics And Neurocrine Biosciences Have Selected Lead Development Candidate In GBA1 Gene Therapy Program For Potential Treatment Of Parkinson's Disease And Other GBA1-mediated DiseasesBenzinga Newsdesk - Apr 16, 2024, 7:06AM
- Nxera Pharma's NBI-1117568, Backed by Neurocrine Biosciences, Successfully Completes Long-Term Preclinical Toxicity ProgramBenzinga Newsdesk - Apr 16, 2024, 3:46AM
Wednesday, April 10, 2024
Wednesday, April 03, 2024
Thursday, March 28, 2024
Thursday, March 21, 2024
Wednesday, March 20, 2024
Tuesday, March 19, 2024
Wednesday, March 13, 2024
- In-Depth Examination Of 8 Analyst Recommendations For Neurocrine BiosciencesBenzinga Insights - Mar 13, 2024, 4:00PM
- Decoding 8 Analyst Evaluations For Neurocrine BiosciencesBenzinga Insights - Mar 13, 2024, 10:03AM
- Oppenheimer Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $200Benzinga Newsdesk - Mar 13, 2024, 8:38AM
Monday, February 26, 2024
- Selection Of The Development Candidate For Friedreich's Ataxia in Collaboration with Neurocrine Biosciences Triggered $5M Milestone Payment To Voyager, Which It Expects To Receive In The First Quarter Of 2024Benzinga Newsdesk - Feb 26, 2024, 7:14AM
- Voyager Therapeutics Announced That The Joint Steering Committee With Its Collaborator Neurocrine Biosciences Has Selected A Lead Development Candidate In Friedreich's Ataxia Program. The Companies Expect The Program To Advance Into Human Trials In 2025Benzinga Newsdesk - Feb 26, 2024, 7:12AM
Thursday, February 15, 2024
Monday, February 12, 2024
Thursday, February 08, 2024
- Citigroup Maintains Neutral on Neurocrine Biosciences, Lowers Price Target to $140Benzinga Newsdesk - Feb 8, 2024, 11:25AM
- Mizuho Maintains Neutral on Neurocrine Biosciences, Raises Price Target to $140-Report released on 7th February 2024Benzinga Newsdesk - Feb 8, 2024, 10:29AM
- Breaking Down Neurocrine Biosciences: 8 Analysts Share Their ViewsBenzinga Insights - Feb 8, 2024, 9:00AM
- Wells Fargo Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $140Benzinga Newsdesk - Feb 8, 2024, 8:42AM
Wednesday, February 07, 2024
- Neurocrine Biosciences Forecasts Ingrezza (Valbenazine) Full Year 2024 Net Product Sales Guidance Of $2.1B-$2.2BBenzinga Newsdesk - Feb 7, 2024, 7:07AM
- Neurocrine Biosciences Reports Ingrezza (valbenazine) Q4 And FY23 Net Product Sales Of $500M And $1.84B, Representing YoY Growth of 25% and 29% RespectivelyBenzinga Newsdesk - Feb 7, 2024, 7:06AM
- Neurocrine Biosciences Q4 Adjusted EPS $1.54 Beats $1.15 Estimate, Sales $515.20M Miss $518.13M EstimateBenzinga Newsdesk - Feb 7, 2024, 7:04AM
- Earnings Scheduled For February 7, 2024Benzinga Insights - Feb 7, 2024, 5:13AM
Tuesday, February 06, 2024
Thursday, January 25, 2024
Tuesday, January 23, 2024
Monday, December 18, 2023
Wednesday, December 13, 2023
Tuesday, December 12, 2023
Thursday, December 07, 2023
Wednesday, December 06, 2023
Tuesday, December 05, 2023
Friday, November 10, 2023
- BMO Capital Maintains Market Perform on Neurocrine Biosciences, Lowers Price Target to $100Benzinga Newsdesk - Nov 10, 2023, 3:12PM
- RBC Capital Maintains Sector Perform on Neurocrine Biosciences, Lowers Price Target to $121Benzinga Newsdesk - Nov 10, 2023, 2:20PM
- Why Is Neurocrine Biosciences Stock Trading Lower Today?Vandana Singh - Nov 10, 2023, 1:43PM